Search

Displaying results 4251 - 4260 of 7455 in total
  1. Drug

    SPG601

    go.drugbank.com/drugs/DB18742
    Investigational

    SPG601 is being investigated for the treatment of fragile X syndrome.

  2. Drug

    D-Leucine

    go.drugbank.com/drugs/DB01746
    Experimental

    An essential branched-chain amino acid important for hemoglobin formation. [PubChem]

  3. Drug

    Bunamidine

    go.drugbank.com/drugs/DB11501
    ExperimentalVet approved

    Bunamidine is a veterinary anti-platyhelmintic agent used for taenia infestations.

  4. Drug

    Belotecan

    go.drugbank.com/drugs/DB12459
    Investigational

    Belotecan has been investigated for the treatment of Epithelial Ovarian Cancer.

  5. Drug

    Fluprednisolone

    go.drugbank.com/drugs/DB09378
    Approved

    A synthetic glucocorticoid with anti-inflammatory properties.

    Categories: Corticosteroids for Systemic Use
  6. Drug

    Baicalein

    go.drugbank.com/drugs/DB16101
    Investigational

    Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  8. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency